Compare
Gilead Sciences, Inc. vs Amgen Inc vs Biogen Inc. vs Qiagen N.V.
| Latest fiscal year | Gilead Sciences, Inc. GILD | Amgen Inc AMGN | Biogen Inc. BIIB | Qiagen N.V. QGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $29.44B | $36.75B | $9.89B | $2.09B |
| Revenue growth (YoY) | +2.4% | +10.0% | +2.2% | +5.7% |
| Gross margin | 78.8% (computed) | 67.2% (computed) | 75.7% (computed) | 62.2% |
| Operating margin | 34.0% | 24.7% | n/a | 22.3% |
| Net margin | 28.9% | 21.0% | 13.1% | 20.3% |
| Net income | $8.51B | $7.71B | $1.29B | $424.88M |
| EPS (Diluted) | $6.78 | $14.23 | $8.79 | $1.94 |
| Operating cash flow | $10.02B | $9.96B | $2.20B | $654.33M |
| Free cash flow | $9.46B | $8.10B | $2.05B | $453.28M |
| Cash & equivalents | n/a | $9.13B | n/a | $839.00M |
| Total assets | $59.02B | $90.59B | $29.44B | $6.28B |
| Total liabilities | n/a | n/a | $11.18B | n/a |
| Shareholders' equity | $22.62B | $8.66B | $18.26B | $3.78B |
| Return on year-end equity | 37.6% | 89.1% | 7.1% | 11.2% |
| Shares outstanding | 1.24B | 538.80M | 146.80M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Gilead Sciences, Inc. | Amgen Inc | Biogen Inc. | Qiagen N.V. |
|---|---|---|---|---|
| Latest | $29.44B Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $9.89B Ended 2025-12-31 | $2.09B Ended 2025-12-31 |
| 1 year earlier | $28.75B Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $9.68B Ended 2024-12-31 | $1.98B Ended 2024-12-31 |
| 2 years earlier | $27.12B Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $9.84B Ended 2023-12-31 | $1.97B Ended 2023-12-31 |
| 3 years earlier | $27.28B Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $10.17B Ended 2022-12-31 | $2.14B Ended 2022-12-31 |
| 4 years earlier | $27.30B Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $10.98B Ended 2021-12-31 | $2.25B Ended 2021-12-31 |